Anixa Biosciences (NASDAQ: ANIX) — Company Overview, News & Financial Data
Anixa Biosciences develops immune system-based cancer treatments, including a breast cancer vaccine and CER-T technology for prostate cancer.
Anixa Biosciences
Anixa Biosciences (NASDAQ:ANIX) is a biotechnology firm focused on harnessing the body's immune system to fight cancer. Dedicated to developing a range of innovative treatments and vaccines, Anixa's operations span from early research to clinical trials. The company is especially known for its work in developing a cancer vaccine technology aimed at preventing breast cancer, as well as chimeric endocrine receptor T-cell (CER-T) technology targeting prostate cancer. With a commitment to advancing healthcare, Anixa's objectives include bringing groundbreaking immunotherapies and vaccines to market, offering new hope in the fight against cancer.
Snapshot
Operations
Products and/or services of Anixa Biosciences
- Breast cancer vaccine development focused on preventing the recurrence and development of triple-negative breast cancer, utilizing immunotherapy approaches.
- Ovarian cancer vaccine, leveraging the same technology platform as the breast cancer vaccine for prevention and inhibitory growth of ovarian tumors.
- CAR-T technology for solid tumors, innovating cellular therapy to target and destroy cancer cells in various solid tumor types.
- Cchek™, a proprietary AI-based platform for early cancer detection, using machine learning to analyze simple blood tests for multiple cancer types.
- Prostate cancer therapy, focusing on a novel approach to treat early-stage prostate cancer non-invasively, aiming to reduce side effects associated with current treatments.
- Collaboration with Cleveland Clinic on developing vaccines, reflecting a strategic partnership to advance prevention therapies for various cancers.
Anixa Biosciences executive team
- Amit KumarCEO, Chairman & Co-Chair of CBAB
- Michael J. CatelaniPresident, COO, CFO & Corporate Secretary
- Pamela D. GarzoneChief Development Officer & Chair Breast Cancer Clinical Advisory Board
Latest news about Anixa Biosciences
Key financials
Reported results for Anixa Biosciences, in USD.
- Market cap
- 106.2M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -11.7M | -10.9M | |
| 0 | -13.8M | -12.6M | |
| 210K | -11M | -9.8M | |
| 2.5B | -13.9M | -13.6M |